A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol...
Pulmonary DiseaseChronic ObstructiveThe objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler (MDI) Chlorofluorocarbon Inhalation Aerosol 2 actuations four times a day in Chronic Obstructive Pulmonary Disease (COPD) patients currently prescribed Combivent® MDI.
Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients
Pulmonary DiseaseChronic ObstructiveThis study is designed to determine the efficacy and safety of a new long-acting beta-agonist for asthma patients (GSK159797) following dosing for 14 days.
Phase 2 Study - Erdosteine in Patients With CB/COPD
Chronic BronchitisChronic Obstructive Pulmonary DiseaseThis clinical study is designed to explore dose ranging and identify methods to demonstrate the efficacy of Erdosteine in patients with stable Chronic Bronchitis associated with Chronic Obstructive Pulmonary Disease.
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary DiseaseChronic ObstructiveThe primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.
Study to Assess GW642444 in Asthma Patients
Pulmonary DiseaseChronic ObstructiveThis is a study of GW642444M, a long-acting beta 2 specific agonist. This study will examine GW642444M via the inhaled route and will assess the efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of GW642444M in persistent asthmatics. This study will be a single-centre, placebo-controlled, dose-ascending, five-way crossover in 30 asthmatic patients. Key assessments: efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics will be assessed by measurement of FEV1, blood pressure, pulse rate, 12-lead ECGs, clinical laboratory safety tests, collection of adverse events and blood samples.
A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary...
Pulmonary DiseaseChronic Obstructive1 moreThe purpose of this study is to assess the safety of GW856553 in COPD patients and to assess its affects on their COPD disease after 14 days.
A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability
Chronic Obstructive Pulmonary Disease (COPD)Rheumatoid Arthritis1 moreThis study is being conducted to measure the amount of study drug that is in your blood after you receive a different type of tablet in each of four study visits.
Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study
Pulmonary EmphysemaChronic Obstructive Pulmonary DiseaseThe purpose of this study is to evaluate the safety and efficacy of the Biologic Lung Volume Reduction System (BLVR) for patients with advanced emphysema refractory to medical therapy.
Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients
Pulmonary DiseaseChronic ObstructiveThe objective of this trial is to determine whether tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio), compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive pulmonary disease (COPD) who participate in pulmonary rehabilitation.
Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable Chronic...
Pulmonary DiseaseChronic ObstructiveThe purpose of this study is to determine whether carbon monoxide is effective in the treatment of stable COPD.